Vericel (VCEL) Cash & Equivalents (2010 - 2026)
Vericel (VCEL) posted Cash & Equivalents of $125.4 million for Q2 2026, up 14.73% sequentially from $109.3 million in Q1 2026, and up 55.71% YoY from $80.5 million in Q2 2025.
Vericel (VCEL) Cash & Equivalents (2010 - 2026) Analysis & Trends
Vericel has reported Cash & Equivalents for 15 years, with the latest figure at $125.4 million in Q2 2026.
- Quarterly Cash & Equivalents rose 55.71% year-over-year to $125.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $125.4 million (up 55.71% YoY) and the FY2025 annual result came in at $100.1 million, up 34.32% from the prior year.
- Cash & Equivalents grew to $125.4 million in Q2 2026 per VCEL's latest filing, from $109.3 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $125.4 million in Q2 2026 and troughed at $43.0 million in Q2 2023.
- A 5-year average of $71.8 million and a median of $64.1 million in 2022 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2025: Cash & Equivalents decreased 25.26% in 2022, then surged 87.04% in 2025.
- Over 5 years, Cash & Equivalents stood at $51.1 million in 2022, then jumped by 35.29% to $69.1 million in 2023, then climbed by 7.86% to $74.5 million in 2024, then soared by 34.32% to $100.1 million in 2025, then rose by 25.28% to $125.4 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $125.4 million, $109.3 million, and $100.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 125.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 125.40 Mn |
| Mar 31, 2026 | 109.30 Mn |
| Dec 31, 2025 | 100.09 Mn |
| Sep 30, 2025 | 100.40 Mn |
| Jun 30, 2025 | 80.50 Mn |
| Mar 31, 2025 | 73.49 Mn |
| Dec 31, 2024 | 74.52 Mn |
| Sep 30, 2024 | 53.68 Mn |
| Jun 30, 2024 | 50.29 Mn |
| Mar 31, 2024 | 62.94 Mn |
| Dec 31, 2023 | 69.09 Mn |
| Sep 30, 2023 | 60.47 Mn |
| Jun 30, 2023 | 43.02 Mn |
| Mar 31, 2023 | 61.83 Mn |
| Dec 31, 2022 | 51.07 Mn |
| Sep 30, 2022 | 65.22 Mn |
| Jun 30, 2022 | 56.05 Mn |
| Mar 31, 2022 | 55.66 Mn |
| Dec 31, 2021 | 68.33 Mn |
| Sep 30, 2021 | 54.55 Mn |